11.48
price up icon4.46%   0.49
after-market Dopo l'orario di chiusura: 11.48
loading

Stoke Therapeutics Inc Borsa (STOK) Ultime notizie

pulisher
Feb 01, 2025

What is Leerink Partnrs' Forecast for STOK FY2025 Earnings? - MarketBeat

Feb 01, 2025
pulisher
Feb 01, 2025

FY2025 Earnings Estimate for STOK Issued By Leerink Partnrs - Defense World

Feb 01, 2025
pulisher
Jan 31, 2025

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Jan 31, 2025
pulisher
Jan 30, 2025

Stoke Therapeutics (NASDAQ:STOK) Trading 6.9% HigherWhat's Next? - MarketBeat

Jan 30, 2025
pulisher
Jan 30, 2025

How to Take Advantage of moves in (STOK) - Stock Traders Daily

Jan 30, 2025
pulisher
Jan 29, 2025

Stoke Therapeutics (NASDAQ:STOK) Trading Down 5.6%What's Next? - MarketBeat

Jan 29, 2025
pulisher
Jan 27, 2025

The 13% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 116% - Yahoo Finance

Jan 27, 2025
pulisher
Jan 24, 2025

Stoke Therapeutics (NASDAQ:STOK) Trading Up 6.3%Here's What Happened - MarketBeat

Jan 24, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Forecasts STOK FY2025 Earnings - Defense World

Jan 23, 2025
pulisher
Jan 22, 2025

Brokers Offer Predictions for STOK FY2025 Earnings - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Possible Signal As Stoke Therapeutics Insiders Sell US$523k In Stock - Simply Wall St

Jan 22, 2025
pulisher
Jan 20, 2025

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - MSN

Jan 20, 2025
pulisher
Jan 19, 2025

When the Price of (STOK) Talks, People Listen - Stock Traders Daily

Jan 19, 2025
pulisher
Jan 18, 2025

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Acquired by Assenagon Asset Management S.A. - MarketBeat

Jan 18, 2025
pulisher
Jan 15, 2025

Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 9.7%Time to Buy? - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

Barclays PLC Raises Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Jan 15, 2025
pulisher
Jan 14, 2025

Is Stoke Therapeutics Inc (NASDAQ: STOK) Still Trending? - Stocks Register

Jan 14, 2025
pulisher
Jan 11, 2025

Head-To-Head Contrast: Inhibitor Therapeutics (OTCMKTS:INTI) and Stoke Therapeutics (NASDAQ:STOK) - Defense World

Jan 11, 2025
pulisher
Jan 11, 2025

Q1 EPS Estimates for Stoke Therapeutics Raised by Wedbush - Defense World

Jan 11, 2025
pulisher
Jan 10, 2025

Stoke Therapeutics Inc (STOK): Worth A Small Bite At $8.92 - Stocks Register

Jan 10, 2025
pulisher
Jan 10, 2025

Wedbush Equities Analysts Raise Earnings Estimates for STOK - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

What is Wedbush’s Estimate for STOK FY2029 Earnings? - Defense World

Jan 10, 2025
pulisher
Jan 09, 2025

Research Analysts Offer Predictions for STOK FY2029 Earnings - MarketBeat

Jan 09, 2025
pulisher
Jan 09, 2025

Learn to Evaluate (STOK) using the Charts - Stock Traders Daily

Jan 09, 2025
pulisher
Jan 08, 2025

Stoke Therapeutics to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 08, 2025
pulisher
Jan 08, 2025

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire

Jan 08, 2025
pulisher
Jan 08, 2025

Analyst maintains OW rating on Stoke Therapeutics as P3 EMPEROR study design finalized - Investing.com Canada

Jan 08, 2025
pulisher
Jan 08, 2025

Needham & Company LLC Reiterates "Buy" Rating for Stoke Therapeutics (NASDAQ:STOK) - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

Stoke Therapeutics (NASDAQ:STOK) Receives "Buy" Rating from HC Wainwright - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

The Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 Experts - Benzinga

Jan 08, 2025
pulisher
Jan 08, 2025

Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results - Yahoo Finance

Jan 08, 2025
pulisher
Jan 07, 2025

Stoke Therapeutics (NASDAQ:STOK) Shares Gap DownTime to Sell? - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

Stoke Therapeutics Gains Regulatory Alignment for Phase 3 Study - TipRanks

Jan 07, 2025
pulisher
Jan 07, 2025

STOKStoke Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Jan 07, 2025
pulisher
Jan 07, 2025

Stoke Therapeutics aligns with regulators on Dravet study - Investing.com

Jan 07, 2025
pulisher
Jan 07, 2025

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome - Business Wire

Jan 07, 2025
pulisher
Jan 06, 2025

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome - Business Wire

Jan 06, 2025
pulisher
Jan 06, 2025

Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $21.29 - MarketBeat

Jan 06, 2025
pulisher
Jan 06, 2025

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Jan 06, 2025
pulisher
Jan 02, 2025

Franklin Resources Inc. Cuts Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Jan 02, 2025
pulisher
Jan 01, 2025

Geode Capital Management LLC Boosts Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat

Jan 01, 2025
pulisher
Jan 01, 2025

Geode Capital Management LLC Buys 76,661 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Jan 01, 2025
pulisher
Dec 31, 2024

Barclays PLC Purchases 47,239 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Dec 31, 2024
pulisher
Dec 31, 2024

Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Holdings Lifted by Barclays PLC - MarketBeat

Dec 31, 2024
pulisher
Dec 29, 2024

When (STOK) Moves Investors should Listen - Stock Traders Daily

Dec 29, 2024
pulisher
Dec 27, 2024

Skorpios Trust Reduces Stake in Stoke Therapeutics Inc - GuruFocus.com

Dec 27, 2024
pulisher
Dec 27, 2024

Stoke therapeutics sees $23 million stock sale by Skorpios Trust - Investing.com Canada

Dec 27, 2024
pulisher
Dec 26, 2024

The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex - Yahoo Finance

Dec 26, 2024
pulisher
Dec 24, 2024

Stoke Therapeutics (NASDAQ:STOK) Trading Down 2.9%Should You Sell? - MarketBeat

Dec 24, 2024
$39.42
price down icon 3.95%
$351.17
price down icon 0.32%
$21.50
price down icon 3.85%
$5.30
price down icon 2.03%
biotechnology ONC
$224.99
price down icon 0.84%
$123.77
price up icon 2.39%
Capitalizzazione:     |  Volume (24 ore):